Longitudinal evolution of O-(2-[18F]-fluoroethyl)-L-tyrosine PET metrics in serial imaging during glioblastoma progression.

BACKGROUND: Most studies evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET for glioblastoma progression rely on single-scan assessments, leaving diagnostic uncertainties in cases with borderline tracer uptake. We evaluated metabolic activity evolution during the transition of glioblastoma progression using serial FET PET to determine whether longitudinal parameter changes improve diagnostic certainty. PATIENTS AND METHODS: Between 2016 and 2026, 182 patients with glioblastoma undergoing 690 dynamic FET PET scans (median, 3; range, 2-12) were retrospectively evaluated. Eligible cases required documented progressive disease according to RANO 2.0 criteria and serial FET PET at least 2 time points (at suspected progression and within a 6-month prior window). Static PET parameters, ie tumor-to-brain ratios (TBRmean, TBRmax) and metabolic tumor volume (MTV), and their longitudinal changes were evaluated according to PET RANO 1.0 criteria, alongside additional dynamic PET parameters (time-to-peak). Single-scan metrics and serial changes were compared in cases with borderline uptake. RESULTS: Ninety patients with 102 confirmed progression events met all selection criteria (median interscan interval, 2.7 months). At progression, TBRmean, TBRmax, and MTV increased significantly (P < .001). Median percentage increases were modest for TBRmean (+4%) and TBRmax (+17%), whereas MTV exhibited a substantial expansion (+182%). In cases with borderline uptake, applying a longitudinal MTV increase criterion of ≥40% per PET RANO 1.0 substantially improved progression detection to up to 89%, yielding a 14% higher diagnostic detection rate compared to single-scan thresholds. CONCLUSIONS: In glioblastomas with documented RANO 2.0 progression, integrating longitudinal MTV changes markedly improves diagnostic certainty over single-scan uptake metrics, particularly in challenging cases with borderline uptake.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/neuonc/noag265
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Longitudinal evolution of O-(2-[18F]-fluoroethyl)-L-tyrosine PET metrics in serial imaging during glioblastoma progression.

Gereon R. Fink, Isabelle Stetter, Norbert Galldiks, Karl‐Josef Langen et al.
1 links
PubMed
Glioma Diagnosis and Treatment
article

Longitudinal evolution of O-(2-[18F]-fluoroethyl)-L-tyrosine PET metrics in serial imaging during glioblastoma progression.

Gereon R. Fink, Isabelle Stetter, Norbert Galldiks, Karl‐Josef Langen, Jurij Rosen, Jan‐Michael Werner, Mirko Kraft, Julia Hilgers, Philipp Lohmann, Keith George Ciantar, Jana-Marie Peplinski, Chistian Filss, Gabriele Stoffels
article en

Abstract

BACKGROUND: Most studies evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET for glioblastoma progression rely on single-scan assessments, leaving diagnostic uncertainties in cases with borderline tracer uptake. We evaluated metabolic activity evolution during the transition of glioblastoma progression using serial FET PET to determine whether longitudinal parameter changes improve diagnostic certainty. PATIENTS AND METHODS: Between 2016 and 2026, 182 patients with glioblastoma undergoing 690 dynamic FET PET scans (median, 3; range, 2-12) were retrospectively evaluated. Eligible cases required documented progressive disease according to RANO 2.0 criteria and serial FET PET at least 2 time points (at suspected progression and within a 6-month prior window). Static PET parameters, ie tumor-to-brain ratios (TBRmean, TBRmax) and metabolic tumor volume (MTV), and their longitudinal changes were evaluated according to PET RANO 1.0 criteria, alongside additional dynamic PET parameters (time-to-peak). Single-scan metrics and serial changes were compared in cases with borderline uptake. RESULTS: Ninety patients with 102 confirmed progression events met all selection criteria (median interscan interval, 2.7 months). At progression, TBRmean, TBRmax, and MTV increased significantly (P < .001). Median percentage increases were modest for TBRmean (+4%) and TBRmax (+17%), whereas MTV exhibited a substantial expansion (+182%). In cases with borderline uptake, applying a longitudinal MTV increase criterion of ≥40% per PET RANO 1.0 substantially improved progression detection to up to 89%, yielding a 14% higher diagnostic detection rate compared to single-scan thresholds. CONCLUSIONS: In glioblastomas with documented RANO 2.0 progression, integrating longitudinal MTV changes markedly improves diagnostic certainty over single-scan uptake metrics, particularly in challenging cases with borderline uptake.

PubMed
Forschungszentrum Jülich (DE), University of Cologne (DE), Universitätsklinikum Aachen (DE), University Hospital Cologne (DE), RWTH Aachen University (DE)
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon